April 26, 2021

Protection of Previous SARS-CoV-2 Infection Is Similar to That of BNT162b2 Vaccine Protection A Three-Month Nationwide Experience from Israel

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity

• [Pre-print, not peer-reviewed] A population-based study in Israel found that the level of protection against reinfection conferred by prior infection with SARS-CoV-2 within the last 6 months was similar to that elicited by the Pfizer-BioNTech vaccine among people who had no prior infection. Vaccine effectiveness against severe disease was 66% for individuals followed from the day of the first dose until 6 days after the second dose.  Overall vaccine efficacy was 94% for those followed from a week after the second dose and beyond. 

Goldberg et al. (Apr 24, 2021). Protection of Previous SARS-CoV-2 Infection Is Similar to That of BNT162b2 Vaccine Protection A Three-Month Nationwide Experience from Israel. Pre-print downloaded Apr 26 from  https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1